Funding
← Back to your selection

DCVC

Activity from announced rounds

Activity in this selectionAI · Series A

DCVC is an investment firm identified by TypeSafe AI as an existing investor and by its own communications as a backer of Shennon Biotechnologies.

Recorded funding activity

TypeSafe turns unstructured inputs into typed decisions and probability scores for automated software. Shennon develops T-cell engager therapies for solid tumors. Separate TypeSafe financings remain separate events under one investor history.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
2
First participation on record · 1 follow-on
Funding in participating rounds
$952M
3 disclosed · full round size, not this investor’s share

By stage

Series A3

By primary sector

AI1
Biotech1
Defense tech1

By country

United States3

Rounds

3 in this selection
TypeSafe AI

Developer infrastructure that turns unstructured inputs into typed decisions and probability scores for automated software workflows.

$870MSeries A
Participant
Kanvas Biosciences

Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy

$48MSeries A
Role not disclosed
Chariot Defense

Chariot Defense develops power-distribution systems for military use.

$34MSeries A
Role not disclosed